Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

Company Raises Non-GAAP Adjusted EPS Guidance for Full-Year 2008

PLYMOUTH, Minn., Oct. 31 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today reported financial results for its fiscal third quarter of 2008 and its updated financial guidance for 2008.

ev3's net sales were $107.0 million in the third quarter of 2008, representing a 65% increase over the same quarter of the prior year, primarily due to the acquisition of FoxHollow. Third quarter revenues included approximately $100.0 million in net product sales and approximately $7.0 million in research collaboration revenues. Net sales, excluding atherectomy and research collaboration revenues, increased 21% in the third quarter of 2008 versus the prior year quarter. By product segment, third quarter neurovascular net product sales increased by 26% and peripheral vascular net sales, excluding atherectomy increased by 19%. Third quarter atherectomy sales were $21.0 million. On a geographic basis, ev3 U.S. and international business grew by 84% and 37%, respectively over the prior year quarter. Reconciliations of non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found immediately following the detail of net sales by geography later in this release.

Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "We are pleased with our performance during the third quarter, both in terms of our sales and bottom line. Third quarter product sales of $100 million were in line with our previous third quarter guidance despite a stronger dollar than was anticipated in our guidance. I am also encouraged that we were able to maintain the growth of our peripheral vascular business in the third quarter despite pressure and distraction that resulted from the activities of new competitors. More specifically, our atherectomy business is still under some pressure due to th
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... oncology intelligence initiative powered by The Arcas Group, announced ... following this month,s annual meeting of the American Society ... expand on previous Quick Polls carried out after the ... efforts after the American Society of Hematology (ASH) annual ...
... Incorporated (NASDAQ: SPEX ) -- an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies -- today announced that its Annual ... will be held on Tuesday, November 15, 2011, ...
... 2011 ,   ... that its,US-subsidiary NextGen Sciences Inc, a leader in ... cerebrospinal,fluid (CSF) multiple protein (multiplex) assay, csf ... qualification . The assay simultaneously measures,43 human CSF ...
Cached Biology Technology:MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 2MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 3Spherix Announces Annual Shareholders Meeting Date 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... in the online edition of Physiological Genomics finds that individuals ... The study offers the first evidence of the role that ... controls sugar entry into the cells has on sugar ... in sugar. The study was conducted by Ahmed ...
... to Critical Data with MobileCop(R) ... ... International Inc.,(OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification and ... Baltimore (MD) Police Department ("BPD"),for additional licenses of BIO-key,s MobileCop software ...
... new ways to stop the progression of cancer, researchers ... discovered a compound that has shown to prevent cancer ... Gene Regulation and Systems Biology. The compound, which ... normal cells from turning into cancer cells and inhibited ...
Cached Biology News:Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 2BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 3Chemical compound prevents cancer in lab 2
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Src cDNA Expression Kit (wild type)...
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: